|drug245||Angiotensin 1-7 Wiki||0.58|
|drug2508||Placebo (Methylcellulose) capsule Wiki||0.58|
|D045169||Severe Acute Respiratory Syndrome NIH||0.08|
|D018352||Coronavirus Infections NIH||0.06|
There are 3 clinical trials
The leading cause of death in patients with COVID19 is a severe inflammatory response caused by a cytokine storm that results in acute respiratory distress syndrome and acute pulmonary insufficiency, as well as dysfunction of several vital organs. Therefore, preventing the occurrence of uncontrolled inflammation is the main goal of the ongoing clinical trials. Chloroquine and tocilizumab, which have the best results, are also prescribed to control inflammation. But it can be said that treatments are the main source of inflammation. Inflammasome NLRP3 is one of the mechanisms involved in many severe inflammatory disorders. Inflammatory activation has already been demonstrated by many viruses. Melatonin, on the other hand, is a hormone in the body that can inhibit Inflammation NLRP3 in addition to various anti-inflammatory effects, especially after severe inflammation. Older adults with lower levels of melatonin and children with maximum levels of melatonin are the risk groups and low-risk groups for the disease, respectively. In the present study, while measuring melatonin in patients with COVID19, its effectiveness as a treatment method along with the common antiviral drug regimen in patients with severe disease will be evaluated.
Description: Immune system modulator. The amount of it is determined by laboratory methodsMeasure: Melatonin Time: up to 10 days
Description: is a type of signaling molecule (a cytokine) that is secreted from immune cells like helper T cells (Th) and macrophages, and certain other cell types that promote inflammation which is measured by serological or analyzer methodMeasure: Inflammatory cytokines Time: up to 10 days
Description: C-reactive protein (CRP) is a protein made by the liver that measured by serological or analyzer methodMeasure: C-reactive protein (CRP) Time: up to 10 days
Description: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions that measured by Physical examination.Measure: Cough Time: up to 10 days
Description: Oxygen saturation of the blood will measure by pulse oximeterMeasure: Oxygen saturation of the blood Time: up to 10 days
Description: Red blood cell sedimentation rate will measure by AutoanalyzerMeasure: ESR Time: up to 10 days
Description: Radiological Treatment Response (CT scan), more than 50% reduction in the affected areaMeasure: Radiological Treatment Response Time: up to 10 days
Description: Cellular pathway active in inflammationMeasure: Inflammatory route Time: up to 10 days
This study is a pilot randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin in adult outpatients suspected to be afflicted with COVID-19.
Description: Evaluate the incidence of serious adverse effects and discontinuation secondary to toxicity through 28 days of follow-up as compared to the control arm as assessed by: Cumulative incidence of serious adverse events (SAEs), Cumulative incidence of Grade 3 and 4 adverse events (AEs), Discontinuation or temporary suspension of the investigational medication (for any reason).Measure: Cumulative Incidence of Treatment-Emergent Adverse Events Time: 28 days
Description: Incidence of COVID-19 related hospitalization at 28 daysMeasure: Hospitalization Time: 28 days
Description: COVID-19 related symptoms (Fever, chills, cough, nasal symptoms, body aches/muscle aches, headache, loss of smell, loss of taste, nausea, vomiting, diarrhea, fatigue, dizziness) that are self-reported and on interview.Measure: COVID-19 related symptoms Time: 28 days
Description: Change from baseline (day 1) as assessed to days 3, 7, 14, and 28Measure: Rate of resolution of COVID-19 related symptoms Time: 28 days
Description: 28-day mortalityMeasure: Mortality Time: 28 days
This study is a randomized, double-blind, controlled clinical trial to evaluate the effects of toremifene and/or melatonin in adults with mild COVID-19.
Description: Score total of 0-12 assessed daily. Each category based on severity of symptoms of Cough, Shortness of breath, Fatigue/tiredness and daily temperature on a rating scale of 0-3.Measure: Peak increase in COVID-19 Sign and Symptom score Time: Screening to 28 days
Description: Daily mean valuesMeasure: Nadir Oxygen Saturation Time: Day 1 through day 14
Description: Daily mean valuesMeasure: Peak Heart Rate Time: Day 1 through day 14
Description: Score total of 0-12 assessed daily. Each category based on severity of symptoms of Cough, Shortness of breath, Fatigue/tiredness and daily temperature on a rating scale of 0-3.Measure: Time to COVID-19 Sign and Symptom score resolution Time: Screening to 28 days
Description: not hospitalized, no limitation of activities (or resumption of normal activity) not hospitalized but limitation on activities hospitalized, not requiring supplemental oxygen hospitalized, requiring supplemental oxygen (low-flow, e.g., nasal prong) hospitalized, requiring non-invasive ventilation and/or high-flow oxygen hospitalized, on invasive ventilation or ECMO deathMeasure: Time to WHO 7-point ordinal scale score of 3 or higher Time: Day 1 to Day 30
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports